Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.07 USD | +1.54% | -2.11% | +60.25% |
May. 13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
May. 13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.25% | 2.55B | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Needham Adjusts Price Target on Merus to $33 From $35, Keeps Buy Rating